Division of Otolaryngology, Tohoku Medical and Pharmaceutical University Hospital, Miyaginoku, Sendai.
Fukase Clinic.
Otol Neurotol. 2019 Sep;40(8):e820-e823. doi: 10.1097/MAO.0000000000002336.
The aim of this article was to investigate the effectiveness and underlying mechanisms of OK-432 therapy in patients with auricular hematomas.
Case series with planned data collection.
We tried this therapy in 47 patients with auricular hematoma between April 2008 and August 2018. We aspirated as much of the fluid content of each lesion as possible with a 21-gage needle. We injected OK-432 solution into the lesion with the same needle that we used for aspiration. We performed this treatment at an outpatient basis without hospitalization.
Disappearance and marked reduction of the lesion were observed in all patients who had this therapy, and local scarring and deformity of the auricle did not occur in any patients. As adverse effects, local pain at the injection site and fever (37-38.5°C) were observed in some cases of the patients who had this therapy. The concentrations of various cytokines in each aspirate before and after OK-432 therapy were investigated. The production of tumor necrosis factor-α, interleukin-6, interleukin-8, interferon gamma, vascular endothelial growth factor, and periostin was significantly elevated in the aspirate fluid after OK-432 therapy.
OK-432 therapy is simple, easy, safe, effective, and can be used as a substitute for surgery in the treatment of auricular hematoma.
本文旨在研究 OK-432 疗法治疗耳廓血肿患者的疗效及其作用机制。
计划收集数据的病例系列。
我们在 2008 年 4 月至 2018 年 8 月期间对 47 例耳廓血肿患者尝试了这种治疗方法。我们用 21 号针尽可能抽吸每个病变的所有液体内容物。我们用与抽吸相同的针将 OK-432 溶液注入病变部位。我们在门诊进行这种治疗,无需住院。
所有接受这种治疗的患者均观察到病变消失和明显缩小,且耳廓无局部瘢痕和畸形。作为不良反应,接受这种治疗的一些患者在注射部位出现局部疼痛和发热(37-38.5°C)。研究了 OK-432 治疗前后每个抽吸物中各种细胞因子的浓度。OK-432 治疗后抽吸液中肿瘤坏死因子-α、白细胞介素-6、白细胞介素-8、干扰素-γ、血管内皮生长因子和骨膜蛋白的产生显著升高。
OK-432 治疗简单、容易、安全、有效,可作为手术治疗耳廓血肿的替代方法。